CNTO6785, a fully human antIInterleukin 17 monoclonal antibody, in patients with rheumatoid arthritis with inadequate response to methotrexate: A randomized, placebo-controlled, phase II, dose-ranging study

• Main Authors: Philip J. Mease, Slawomir Jeka, Juan Jose Jaller, Tasanee Kitumnuaypong, Worawit Louthrenoo, Herman Mann, Galina Matsievskaia, Enrique R. Soriano, Bin Jia, Caihong Wang, Jing Nie, Elizabeth Hsia
• Format: Journal
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040077437&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/58776
• Institution: Chiang Mai University

Copyright © 2018. All rights reserved. Objective: To evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CNTO6785, a fully human monoclonal antibody that binds to human interleukin 17A, in patients with active rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX...